A trial of CAN1012 for early breast changes (DCIS and LCIS)
Part of Cancer, Skin clinical trials.
This trial tests a new drug called CAN1012 in people with pre-cancerous breast conditions called DCIS or LCIS. It aims to see if the drug can help before invasive cancer develops.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have DCIS or LCIS confirmed by a biopsy, with a single spot between 1 cm and 5 cm on imaging.
- You must be 18 years or older.
- You must be in generally good health, able to do daily activities with little or no help.
- You must have adequate blood counts and kidney/liver function.
- You must agree to use non-hormonal birth control during the study and for 165 days after the last dose.
- You cannot have certain medical conditions or take specific medications, like high-dose steroids or hormonal birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
This study tests a new drug called CAN1012 to treat oral epithelial dysplasia, which are pre-cancerous changes in the mouth lining. The goal is to see if this drug can help prevent these changes from becoming cancer.
This trial studies whether removing the abnormal breast cells with breast-conserving surgery only (without additional treatment) is enough for people with low-risk ductal carcinoma in situ (DCIS). It may help some patients avoid extra treatments if their risk is very low.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
This trial tests whether taking endocrine therapy (medication that blocks estrogen) can help some women with very early breast changes (like DCIS or ADH) avoid surgery. It is for women whose cells are strongly estrogen receptor positive and not HER2 positive.
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.